Nipent (Pentostatin) Injection shortage
Nipent (pentostatin injections) is on the FDA’s drug shortage list as of Nov 21, 2026.
- The company reporting it has not given the FDA a specific reason.
- Status
- FDA term: “Current”
- Products on the record
- 1
- Category
- First posted
- Aug 27, 2026
- Last updated
- Nov 9, 2026
This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD Compiled from public FDA (openFDA) and CMS (Medicaid) data sources. Editorial policy
The Bottom Line
Nipent (pentostatin) injection is in current shortage, and the 10 mg single-dose vial has no listed source right now. Among the makers reporting to the FDA, Hospira lists no supply, no other maker lists this medicine in our records, and Hospira's next delivery is estimated for December 2028.
Don’t stop or change your therapy on your own — ask your pharmacist about other companies’ versions and your prescriber about a long-term plan.
Is Nipent Still in Shortage? Status as of Nov 21, 2026
Yes, still current as of Nov 21, 2026. Right now we could not find any company still making the one strength on the record. The one company that reported this shortage does not report any supply, and we could not find another company that sells it. Your pharmacy may still need to order it.
The charts count only the companies that reported this shortage to the FDA; we could not confirm another company listing it (see below).
Availability of the Affected Products
From the FDA shortage report: 1 product
Is Every Strength Still Made?
A medicine often comes in several strengths, and more than one company may make each. This shows whether at least one company still makes each strength on the record: a company on the shortage report that still has supply, or another company that sells it.
0 of 1 strength
- 10 mg, single dose vialNo company found making it
Reporting Companies With Supply
Among the 1 company that reported this shortage
0 of 1 reporting
Other Companies
We couldn’t confirm another company listing Pentostatin Injection in the FDA NDC Directory without a shortage report. Ask your pharmacist whether a different company’s version or another strength can be ordered.
Shortage Timeline
- Nov 9, 2026 Currently in shortage 1 of 1 product affected.
- Aug 27, 2026 First reported to the FDA 1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
Which Nipent Products Are Affected, by Company
Only the companies that told the FDA about a supply problem are listed here, so other companies may still have stock.
Company: Hospira, Inc., a Pfizer Company
-
Nipent Injection, 10 mg, single dose vial
- Strength
- 10 mg, single dose vial
- Availability
Notes: Next Delivery and Estimated Recovery: December 2028
Reason: Other
Why Is Nipent in Shortage?
A note from Dr. Brian Staiger, PharmD · Written Nov 14, 2026
I know it's frustrating to hear that a medicine is hard to find, so let me explain what the FDA report says. Hospira, a Pfizer company, reported a shortage of Nipent (pentostatin injection), the 10 mg single-dose vial (NDC 0409-0801-01). That product is listed as currently unavailable.
The FDA lists the reason only as "Other," which is a general category. Hospira did not share a specific public reason for the shortage, so I can't tell you what caused it. I don't want to guess.
The one date in the report is December 2028. The manufacturer lists that as both the "next delivery" and the estimated recovery for this vial. This report covers only Hospira's Nipent vial. It doesn't speak for any other company that may make pentostatin.
FDA Reason Codes
What Should I Do If I Take Nipent?
A note from Dr. Brian Staiger, PharmD · Written Nov 14, 2026
Pentostatin Injection (brand name Nipent) is currently on the FDA drug-shortage list. Because this medicine is usually given in a clinic or hospital, your care team is likely already aware of the shortage and planning around it.
Only one strength is listed: 10 mg, single dose vial. Right now, there is no available source for this strength among the companies reporting the shortage. No strengths are listed as still available.
The one manufacturer on this report, Hospira, Inc. (a Pfizer company), lists its product as unavailable. The FDA lists the reason only as "Other." The company estimates its next delivery and recovery for December 2028. This report covers only that manufacturer, and our records do not list other makers of this same medicine. Local supply may also differ from this national data.
What you can do:
- Do not skip, delay, or change any treatment on your own.
- Ask your treatment team or pharmacy whether they can still get pentostatin. Pharmacies can check wholesalers and other sources.
- If it cannot be found, ask your prescriber about options, such as an alternative treatment chosen for your situation.
- The manufacturer's contact number is listed on this page for reference, though pharmacies usually handle these calls.
This is general information, not individual medical advice. Your prescriber is the best guide for your care.
Quick checklist for the pharmacy counter
- Ask your pharmacy to check other companies’ versions, other strengths, package sizes, and nearby stores.
- If this is part of an ongoing or essential regimen (for example HIV, seizure, heart, transplant, diabetes or mental-health medicines), arrange continued supply before you run out rather than rationing doses.
Therapeutic Equivalents and Pricing 1 product
Other products the FDA rates as interchangeable with the affected strengths, with what pharmacies pay for each and whether pharmacies are still buying it. Cheapest first.
| Product | Manufacturer | Package | Pharmacy cost per unit (NADAC) | FDA rated equivalent | Availability |
|---|---|---|---|---|---|
| Nipent 2 mg/mLNDC 00409-0801-01 | Hospira, | 1 vial | — | AP | FDA listed |
These have the same ingredient, strength, form and route, and the FDA rates them as substitutes (an “AB” rating in its Orange Book). The price is what pharmacies pay on average (CMS’s NADAC survey), not what you pay. Availability comes from recent pharmacy prices, not a stock check.
Other Drugs in the Same Treatment Class
These are different medicines — not other versions of Nipent — that fall in the same broad treatment class (antineoplastic - antimetabolites). They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Codes & Classification for pharmacists and billers
- GCN Seq No
- 016510
- GCN
- 19901
- HICL code
- 006301
- Ingredient (HICL)
- Pentostatin
- HIC1 code
- V
- Therapeutic class — broad (HIC1)
- Neoplasms
- HIC2 code
- V1
- Therapeutic class — intermediate (HIC2)
- Antineoplastic Drugs
- HIC3 code
- V1B
- Therapeutic class — specific (HIC3)
- Antineoplastic - Antimetabolites
- AHFS code
- 10:00.00.00
- AHFS class
- Antineoplastic Agents
- FDB label name
- NIPENT 10 MG VIAL
- FDB brand name
- Nipent
- Legend status
- F — Federal legend — prescription drug or device
Where does this data come from? Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.
Other Oncology Shortages
- Valstar Preservative Free (Valrubicin) SolutionA company is discontinuing its version · 1 product
- Leuprolide Acetate InjectionA company is discontinuing its version · 1 product
- Melphalan Hydrochloride InjectionA company is discontinuing its version · 1 product
- Fulvestrant InjectionA company is discontinuing its version · 1 product
- Treanda (Bendamustine Hydrochloride) InjectionA company is discontinuing its version · 1 product
- Lorbrena (Lorlatinib) TabletA company is discontinuing its version · 1 product
- Vizimpro (Dacomitinib) TabletA company is discontinuing its version · 3 products
- Ibrance (Palbociclib) CapsuleA company is discontinuing its version · 2 products
Nipent Shortage FAQs
Is Nipent still in shortage or on backorder?
Yes — as of Nov 21, 2026 the FDA lists Nipent (pentostatin injections) as a current shortage (status: “Current”, first reported Aug 27, 2026). The FDA’s record for this shortage covers 1 product from 1 company. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which strengths of Nipent are affected?
The FDA record covers 1 strength: 10 mg, single dose vial. Right now we could not find any company still making it: the companies that reported the shortage say they are out, and no other company we found sells it. Ask your pharmacist and prescriber about options before you run out.
Why is Nipent on backorder?
The company reporting it has not given the FDA a specific reason.
Is Nipent discontinued?
No. No company on this FDA record has told the FDA it is discontinuing pentostatin injections. It is listed as a shortage, which is a supply problem, not a medicine being withdrawn.
Which Nipent products are affected?
Nipent Injection, 10 mg, single dose vial (NDC 00409-0801-01). The full per-NDC list (availability, company and status) is in the table above — each NDC links to its own page.
When will Nipent be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Is the brand or the generic affected?
Only the brand (Nipent) is on this FDA record; it lists no generic pentostatin injections. Availability can still differ between companies and package sizes — check the per-NDC table and confirm with your pharmacy.
What should I do if I take Nipent?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another company or a different strength or package size, and ask your prescriber about a long-term plan before your supply runs out.
How to Read the Supply-Risk Rating
Each drug in shortage gets one point for each of five risk factors that apply to it (listed with its rating). It is our estimate across the country, not a check of your pharmacy’s shelves.
- Low0 to 2 risk factors Your pharmacy can often still get it, though it may need to be ordered.
- Medium3 risk factors Supply is tight in several ways. Finding it may take some calling around.
- High4 or 5 risk factors, or no company found making it Few companies are left making it, or some strengths have no maker at all. It may be hard to find for a while.Nipent is rated High: 4 of 5 risk factors, rated the highest because no company was found making it.
Back to this drug’s rating ↑ · How we rate supply risk, in full
Where This Data Comes From
- The FDA’s drug shortage database, checked every day: the companies, their products and the codes on their boxes (NDCs), the status, the reason and the dates. See the FDA’s record for this shortage ↗
- The FDA’s NDC Directory: the other companies that make the same medicine, which the supply-risk rating counts.
- First Databank and CMS NADAC: matching the same medicine across companies, and what pharmacies pay for the equivalents.
For reference only. Check with your pharmacist, the drug’s maker or the FDA before acting on it.